帕金森氏病与便秘的非药物干预措施的比较有效性:系统性审查和网络元分析
Peiying Zhang1, Xiaojuan Su2, Xuan Han1
1College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in neurology
|June 18, 2025
概括
物理剂 (PA) 和基于证据的护理 (EBN) 显示出在帕金森病 (PD) 中控制便秘的卓越疗效. 这些非药物干预措施提供了有前途的好处,尽管需要进一步的研究.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
- 基于证据的实践.
背景情况:
- 帕金森病 (PD) 经常出现便秘,严重影响患者的生活质量.
- 越来越多地探索非药物干预措施来管理与PD相关的便秘.
- 这些干预措施的比较疗效数据仍然有限.
研究的目的:
- 进行网络元分析 (NMA),比较各种非药物干预措施在帕金森病中便秘的疗效.
- 建立这些干预措施的基于证据的层次结构.
主要方法:
- 在七个主要数据库的系统搜索中,确定了符合条件的随机对照试验 (RCT) 到2024年8月.
- 涉及881名患者的12个RCT评估了补充和替代医学 (CAM),基于证据的护理 (EBN),物理剂 (PA) 和传统中医药 (TCM).
- 为了估计相对治疗效果,进行了频率网络元分析,并使用Cochrane风险偏差工具评估了方法质量.
主要成果:
- 与对照条件相比,EBN和PA都显示出明显更高的疗效 (p < 0.05).
- 国家药物管理局证实了PA和EBN在被动控制,安慰剂和虚假干预措施中的优越性.
- 确定有效性等级是:物理代理 (最有效) > 基于证据的护理 > 补充和替代医学 > 中国传统医学 (最不有效).
结论:
- 非药物干预,特别是基于PA的方法,为PD的便秘管理提供了临床上有意义的好处.
- 这些发现表明PA和EBN是PD相关便秘的有效策略.
- 由于研究的局限性,需要进一步进行高质量的RCT来确认这些结果并优化治疗方案.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
353
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
353
Drugs Affecting GI Tract Motility: Other Laxatives
486
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
486
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
421
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
421
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
645
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
645
Irritable Bowel Syndrome III: Medical and Nursing Management
322
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
322


